紫杉类药物每周与三周方案比较治疗非小细胞肺癌的系统评价_《中国循证医学杂志》

作者：

1. 兰州大学循证医学中心（兰州 730000）；2. 天津医科大学总医院肿瘤科（天津 300052）;

关键词：

紫杉醇多西紫杉醇非小细胞肺癌随机对照试验 Meta 分析系统评价

DOI：

10.7507/1672-2531.20100456

视频：

导出 下载 收藏 扫码 引用

摘要 全文 图表 视频 参考文献 施引文献 补充材料

目的　系统评价紫杉类药物每周与三周方案治疗非小细胞肺癌的疗效和安全性。
方法　检索1966 ～ 2008 年5 月Cochrane 图书馆、PubMed、EMbase 及CBM 数据库，搜集紫杉类药物每周与三周方案组对比治疗非小细胞肺癌的随机对照试验（RCT）。按Cochrane 手册4.2.6 RCT 的质量评价标准对纳入研究的方法学质量进行评价，并使用RevMan 5.0 软件进行Meta 分析。
结果　共纳入9 个RCT，包括1 438 例患者。每周和三周方案组在1 年生存率［紫杉醇：RR=1.24，95%CI（0.83，1.86）；多西紫杉醇：RR=0.80，95%CI（0.51，1.23）］及总反应率［紫杉醇：RR=1.03，95%CI（0.72，1.49）；多西紫杉醇：RR=0.98 95%CI（0.64，1.49）］方面差异无统计学意义；每周方案组中性粒细胞减少［紫杉醇：RR=0.74，95%CI（0.56，0.97）；多西紫杉醇：RR=0.22，95%CI（0.16，0.30）］较三周组发生率低，但在贫血等其它毒性方面差异无统计学意义。
结论　紫杉类药物每周及三周方案治疗非小细胞肺癌疗效相似，每周方案粒细胞减少症较三周方案发生率低，其它毒性发生率相似。

引用本文： 邵宜,马力,马彬,田金徽,杨克虎. 紫杉类药物每周与三周方案比较治疗非小细胞肺癌的系统评价. 中国循证医学杂志, 2010, 10(5): 602-608. doi: 10.7507/1672-2531.20100456 复制

1.	Parkin DM, Bray FI, Devessa SS. Cancer burden for the year 2000: the global picture. Eur J Cancer, 2001, 37(Suppl 8): S4-S66.
2.	American Cancer Society: Cancer facts and figures 2008. [2008- 07-20]. http: //www.cancer.org/.
3.	Non-small lung cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 1995, 311(7010): 899-909.
4.	Noble J, Ellis PM, Mackay JA, et al. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol, 2006, 1(9): 1042-1058.
5.	Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18(10): 2095-2103.
6.	Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinumcontaining chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, 2000, 18(12): 2354-2362.
7.	von Pawel J, Wagner H, Niederle N, et al. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin Oncol, 1996, 23(6 Suppl 16): 47-50.
8.	Nakamura Y, Kunitoh H, Kubota K, et al. Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum- based chemotherapy. Am J Clin Oncol, 2003, 26(5): 459-464.
9.	Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer . J Clin Oncol, 1998, 16(10) : 3353-3361.
10.	Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II trial of weekly docetaxel in second-line therapy for non-small cell lung carcinoma. Cancer, 2001, 92(8): 2158-2163.
11.	Belani CP, Dakhil S, Waterhouse DM, et al. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol, 2007, 18(1): 110-115.
12.	Socinski MA, Ivanova A, Bakri K, et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol, 2006, 17(1): 104-109.
13.	Camps C, Massuti B, Jiménez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced nonsmall- cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol, 2006, 17(3): 467-472.
14.	Chen YM, Shih JF, Perng RP, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest, 2006, 129(4): 1031-1038.
15.	Gervais R, Ducolone A, Breton JL, et al. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol, 2005, 16(1): 90-96.
16.	Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL01 study. Br J Cancer, 2004, 91(12): 1996-2004.
17.	Lai CL, Tsai CM, Chiu CH, et al. Phase II randomized trial of triweekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol, 2005, 35(12): 700-706.
18.	Schuette W, Nagel S, Blankenburg T, et al. Phase III study of secondline chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol, 2005, 23(33): 8389-8395.
19.	Lilenbaum R, Rubin M, Samuel J, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol, 2007, 2(4): 306-311.
20.	Massimo DM, Francesco P, Paolo C, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced nonsmall- cell lung cancer. J Clin Oncol, 2007 25(11): 1377-1382.

1. Parkin DM, Bray FI, Devessa SS. Cancer burden for the year 2000: the global picture. Eur J Cancer, 2001, 37(Suppl 8): S4-S66.
2. American Cancer Society: Cancer facts and figures 2008. [2008- 07-20]. http: //www.cancer.org/.
3. Non-small lung cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 1995, 311(7010): 899-909.
4. Noble J, Ellis PM, Mackay JA, et al. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol, 2006, 1(9): 1042-1058.
5. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18(10): 2095-2103.
6. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinumcontaining chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, 2000, 18(12): 2354-2362.
7. von Pawel J, Wagner H, Niederle N, et al. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin Oncol, 1996, 23(6 Suppl 16): 47-50.
8. Nakamura Y, Kunitoh H, Kubota K, et al. Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum- based chemotherapy. Am J Clin Oncol, 2003, 26(5): 459-464.
9. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer . J Clin Oncol, 1998, 16(10) : 3353-3361.
10. Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II trial of weekly docetaxel in second-line therapy for non-small cell lung carcinoma. Cancer, 2001, 92(8): 2158-2163.
11. Belani CP, Dakhil S, Waterhouse DM, et al. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol, 2007, 18(1): 110-115.
12. Socinski MA, Ivanova A, Bakri K, et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol, 2006, 17(1): 104-109.
13. Camps C, Massuti B, Jiménez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced nonsmall- cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol, 2006, 17(3): 467-472.
14. Chen YM, Shih JF, Perng RP, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest, 2006, 129(4): 1031-1038.
15. Gervais R, Ducolone A, Breton JL, et al. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol, 2005, 16(1): 90-96.
16. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL01 study. Br J Cancer, 2004, 91(12): 1996-2004.
17. Lai CL, Tsai CM, Chiu CH, et al. Phase II randomized trial of triweekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol, 2005, 35(12): 700-706.
18. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of secondline chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol, 2005, 23(33): 8389-8395.
19. Lilenbaum R, Rubin M, Samuel J, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol, 2007, 2(4): 306-311.
20. Massimo DM, Francesco P, Paolo C, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced nonsmall- cell lung cancer. J Clin Oncol, 2007 25(11): 1377-1382.

《中国循证医学杂志》

紫杉类药物每周与三周方案比较治疗非小细胞肺癌的系统评价

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

《中国循证医学杂志》

紫杉类药物每周与三周方案比较治疗非小细胞肺癌的系统评价

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

摘要全文图表视频参考文献施引文献补充材料